newsfilter
← Latest News
ClinicalTrials.gov·

A Phase 3 Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib - NCT05734105

Progression-free Survival (PFS), Objective Response Rate (ORR), Overall Survival (OS)